Latest Amides Stories
Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
RIDGEFIELD, Conn., June 20, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate).
German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States.
New research study “Antibiotics Partnering Terms and Agreements” worked out by CurrentPartnering is now available at MarketPublishers.com. London, UK (PRWEB)
A recent settlement announcement involving Pradaxa has been announced by the manufacture, Boehringer Ingelheim. Toledo, Ohio (PRWEB) June 05, 2014 Boehringer
Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis
Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma PETACH TIKVA, Israel, June 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Boehringer Ingelheim Agrees to Pay $650 Million To Settle 4,000 Pradaxa Lawsuit That Allege Internal Bleeding After Taking The Prescription Medication. Columbus,
The Firm is evaluating Pradaxa bleeding claims on behalf of individuals who allegedly suffered life-threatening episodes of internal hemorrhaging due to their use of Pradaxa. New
- The act of sweetening by admixture of some saccharine substance.